{"nctId":"NCT00262522","briefTitle":"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","startDateStruct":{"date":"2005-11"},"conditions":["Human Immunodeficiency Virus Infections"],"count":664,"armGroups":[{"label":"LPV/r 800/200 mg QD Tablet","type":"EXPERIMENTAL","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)"]},{"label":"LPV/r 800/200 mg QD SGC (Through Week 8)","type":"EXPERIMENTAL","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)"]},{"label":"LPV/r 400/100 mg BID Tablet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)"]},{"label":"LPV/r 400/100 mg BID SGC (Through Week 8)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)"]}],"interventions":[{"name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral na√Øve adults at least 18 years of age with \\< 7 days of prior antiretroviral therapy.\n* Subjects had plasma HIV-1 ribonucleic acid (RNA) levels \\>= 1,000 copies/mL at screening and were not acutely ill.\n* Female subjects were nonpregnant and nonlactating.\n\nExclusion Criteria\n\n* Subjects were excluded if screening laboratory analyses showed any of the following abnormal laboratory results:\n\n  * Presence of hepatitis B surface antigen (HBsAg)\n  * Hemoglobin \\<= 8.0 g/dL\n  * Absolute neutrophil count \\<= 750 cells/microliter\n  * Platelet count \\<= 50,000 per mL\n  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>= 3.0 x Upper Limit of Normal (ULN)\n  * Calculated creatinine clearance \\< 50 mL/min","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"54.8","spread":null},{"groupId":"OG002","value":"44.6","spread":null},{"groupId":"OG003","value":"49.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/mL at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG002","value":"75.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/mL at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 96 in CD4+ T Cell Counts","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"238.4","spread":"10.02"},{"groupId":"OG002","value":"254.0","spread":"10.00"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":333},"commonTop":["Diarrhea","Nausea","Nasopharyngitis","Vomiting","Fatigue"]}}}